Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99per week for the first 24weeks
Just $1.99per week for the first 24weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

Investing in the broad market is easy, thanks to the proliferation of exchange-traded funds. One click gives you exposure to the entire S&P/TSX Composite Index, the U.S. S&P 500, the Dow, or whatever.

You can build a global portfolio with just half a dozen inexpensive ETFs. It’s an easy and generally profitable way to invest.

But at the end of the day, your results will be no better than those of the overall markets. That’s because you’ll own a portfolio that includes both stars and clunkers. Focusing instead on outperforming winning stocks, you could consistently outperform an all-ETF portfolio.

Story continues below advertisement

Of course, that’s easier said than done. Money managers are paid big bucks to try to achieve that goal and most don’t succeed. That’s why I suggest investing most of your money, say 75 per cent, in broadly based ETFs. The rest should be carefully allocated to stocks with the greatest potential for above average long-range returns.

How do you identify them? It’s an investment axiom that past performance is no guarantee of future results. But the reality is that a company with a long history of superior results in good times and bad is unlikely to suddenly reverse direction. Yes, it can happen, but not often. Betting on proven winners is likely to be more rewarding long-term than taking a shot on a company with a great story but no profits.

Someone recently asked me: If I had to invest all my money in one stock, which would it be? Microsoft Corp. (MSFT-Q) was the first name that popped into my head. Its Windows operating system has been powering most of the world’s computers since the 1990s and there’s every reason to believe that dominance will continue.

Its Office suite (Word, Excel, etc.) has been successfully transformed from a one-off purchase to a lucrative subscription business model. The company is a leader in cloud storage, virtual communications software and gaming, and is in the process of enhancing its artificial intelligence business.

The result is a bonanza for investors. Microsoft has delivered a five-year average annual rate of return of 38.5 per cent. You won’t find any broadly based ETF that comes close.

We recommended Microsoft in my Internet Wealth Builder newsletter in April, 2018, at US$90.23. The stock closed Monday at US$261.55 for a gain to date of 189.8 per cent plus dividends.

Another company that falls into this category is Thermo Fisher Scientific Inc. (TMO-N). Based in Waltham, Mass., it’s a leading manufacturer of scientific instrumentation including laboratory and health monitoring equipment. It also provides software and services to the health care, biotechnology and pharmaceutical industries, as well as to governments and academia.

Story continues below advertisement

Its brands include Thermo Scientific, Fisher Scientific, Applied Biosystems, Invitrogen, Patheon and Unity Lab Services.

Thermo Fisher is deeply involved in the fight against COVID-19, particularly in analysis of the virus, diagnosis and personal protection. The company is working with government agencies and researchers to ensure priority access to instruments, safety supplies and other products to combat the outbreak.

The company was created in 2006 by the merger of Thermo Electron and Fisher Scientific. Today it has annual revenue in excess of US$30-billion and a market cap of about US$190-billion.

In February, Thermo Fisher released very strong fourth-quarter and 2020 year-end results. For the quarter, revenue was up 54 per cent year over year to US$10.55-billion. Net income was US$2.5-billion on a GAAP basis (US$6.24 a share, fully diluted) compared with US$1-billion (US$2.49) in the same period of 2019.

For the full year, revenue increased 26 per cent to US$32.2-billion. Net income was US$6.4-billion (US$15.96 a share), up from US$3.7-billion (US$9.17) in 2019.

The company announced this month that it is buying PPD Inc., a leading global provider of clinical research services to the pharma and biotech industry, for a total cash purchase price of US$17.4-billion plus the assumption of approximately US$3.5-billion of net debt. Wilmington, N.C.-based PPD is a leader in the growing US$50-billion clinical research services industry and operates in nearly 50 countries. In 2020, the company generated revenue of US$4.7-billion.

Story continues below advertisement

In February, Thermo Fisher announced it is increasing the quarterly dividend by 18 per cent to 26 US cents (US$1.04 a year). The stock yields 0.2 per cent at the new rate. The company also has a share buyback program.

Like Microsoft, the company has a history of above average performance. The five-year average annual compound rate of return is 27.9 per cent.

Full disclosure: The author personally owns shares of Microsoft.

Be smart with your money. Get the latest investing insights delivered right to your inbox three times a week, with the Globe Investor newsletter. Sign up today.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow the author of this article:

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Tickers mentioned in this story
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies